Severe Pneumonia Caused by Corynebacterium striatum in Adults, Seoul, South Korea, 2014–2019

Yun Woo Lee¹, Jin Won Huh¹, Sang-Bum Hong, Jiwon Jung, Min Jae Kim, Yong Pil Chong, Sung-Han Kim, Heungsup Sung, Kyung-Hyun Do, Sang-Oh Lee, Chae-Man Lim, Yang Soo Kim, Younsuck Koh, Sang-Ho Choi

SYNOPSIS

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; and (4) view/print certificate. For CME questions, see page 2364.

Release date: October 19, 2022; Expiration date: October 19, 2023

Learning Objectives

Upon completion of this activity, participants will be able to:

• Assess the proportion, demographics, underlying diseases, and pathogens of severe Corynebacterium striatum hospital-acquired pneumonia in adults compared with those of severe methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia, based on a retrospective study

• Evaluate the clinical characteristics, laboratory findings, and outcomes of severe Corynebacterium striatum hospital-acquired pneumonia in adults compared with those of severe methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia, based on a retrospective study

• Determine the clinical implications of the proportion, clinical characteristics, and outcomes of severe Corynebacterium striatum hospital-acquired pneumonia in adults compared with those of severe methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia, based on a retrospective study

CME Editor

Amy J. Guinn, BA, MA, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Amy J. Guinn, BA, MA, has disclosed no relevant financial relationships.

CME Author

Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay, MD, has the following relevant financial relationships: formerly owned stocks in AbbVie Inc.

Authors

Yun Woo Lee, MD, MS; Jin Won Huh, MD, PhD; Sang-Bum Hong, MD, PhD; Jiwon Jung, MD, PhD; Min Jae Kim, MD, PhD; Yong Pil Chong, MD, PhD; Sung-Han Kim, MD, PhD; Heungsup Sung, MD, PhD; Kyung-Hyun Do, MD, PhD; Sang-Oh Lee, MD, PhD; Chae-Man Lim, MD, PhD; Yang Soo Kim, MD, PhD; Younsuck Koh, MD, PhD; and Sang-Ho Choi, MD, PhD.

¹These authors contributed equally to this article.

Authors affiliation: University of Ulsan College of Medicine, Seoul, South Korea

DOI: https://doi.org/10.3201/eid2811.220273
We investigated the proportion and characteristics of severe Corynebacterium striatum pneumonia in South Korea during 2014–2019. As part of an ongoing observational study of severe pneumonia among adult patients, we identified 27 severe C. striatum pneumonia cases. Most (70.4%) cases were hospital-acquired, and 51.9% of patients were immunocompromised. C. striatum cases among patients with severe hospital-acquired pneumonia (HAP) increased from 1.0% (2/200) during 2014–2015 to 5.4% (10/185) during 2018–2019, but methicillin-resistant Staphylococcus aureus (MRSA) infections among severe HAP cases decreased from 12.0% to 2.7% during the same timeframe. During 2018–2019, C. striatum was responsible for 13.3% of severe HAP cases from which bacterial pathogens were identified. The 90-day mortality rates were similarly high in the C. striatum and MRSA groups. C. striatum was a major cause of severe HAP and had high mortality rates. This pathogen is emerging as a possible cause for severe pneumonia, especially among immunocompromised patients.

Corynebacterium striatum is a nonlipophilic, fermentative coryneform bacterium that commonly occupies the normal flora of the skin and oropharynx (1). Although C. striatum isolated from clinical specimens has frequently been considered a contaminant, it is increasingly recognized as a pathogen of various infections, including central line-associated bactereemia (2), endocarditis (3), and pleuropulmonary infection (4–6). In 1980, C. striatum was reported as a cause of pleuropulmonary infection in a patient with chronic lymphocytic leukemia (4). In 2018, a group of researchers in the United States reported 3 cases of community-acquired pneumonia (CAP) in which Corynebacterium species were the predominant isolate and suggested that Corynebacterium species are a noteworthy clinical cause of pneumonia (6). However, scarce information is available on the incidence, clinical characteristics, and outcomes of severe C. striatum pneumonia in critically ill adult patients, because previous studies included ≤5 patients with severe C. striatum pneumonia, except those reporting hospital outbreak events.

Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of severe hospital-acquired pneumonia (HAP), and the clinical characteristics and outcomes of severe MRSA pneumonia are well-documented. Therefore, comparing C. striatum and MRSA pneumonia could clarify the clinical characteristics of C. striatum pneumonia for clinicians. We investigated the proportion, clinical characteristics, and outcomes of severe C. striatum pneumonia in adults and compared those aspects with those for severe MRSA pneumonia.

Methods

Study Design, Setting, Data Collection, and Patient Selection

This study is part of an ongoing prospective observational study on severe pneumonia in critically ill adult (≥16 years of age) patients at Asan Medical Center, a 2,700-bed tertiary referral center in Seoul, South Korea. Since March 2010, we have prospectively identified all adult patients admitted to the 28-bed medical intensive care unit (ICU) who were clinically suspected of having severe pneumonia and monitored them until hospital discharge (7–10). We collected data on patient demographics; underlying diseases or conditions; category of pneumonia; initial clinical manifestations; laboratory, microbiologic, and radiologic findings; treatment; complications; and mortality rates. For this study, we investigated patients with severe C. striatum pneumonia who were admitted to the medical ICU during January 2014–December 2019. This study was approved by the institutional review board of Asan Medical Center (IRB no. 2010–0079), which waived the need for informed consent due to the observational nature of the study.

Definitions

We defined and categorized pneumonia as previously stated (11–13). We defined severe pneumonia as the necessity for mechanical ventilation or having septic shock at ICU admission (12). We defined sepsis and septic shock according to Sepsis-3 criteria (14). We defined immunocompromised state as described previously (15).

C. striatum Identification and Antimicrobial Susceptibility Testing

We cultured sputum specimens on a 5% sheep blood plate and MacConkey agar (Synergy Innovation, http://www.synergyinn.com). When coryneform gram-positive bacilli were isolated, we identified and performed antimicrobial susceptibility testing for specimens that were urea positive or from the ICU (16). We quantitatively cultured bronchoalveolar lavage specimens on chocolate agar and identified and performed susceptibility testing when coryneform gram-positive bacilli exclusively grew at ≥10^5 CFU/mL (16). Until August 2015, our facility used the triple sugar iron, motility, API Coryne (bioMérieux-Vitek, https://www.biomerieux.com) system to identify coryneform gram-positive rods. In September 2015, our facility began using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Bruker Daltonik, https://www.bruker.
We determined antimicrobial susceptibility profiles by ETEST (bioMérieux-Vitek) with MHF medium (Mueller-Hinton agar with 5% horse blood + 20 mg/L β-NAD; bioMérieux-Vitek). We used the Clinical and Laboratory Standards Institute M45 guideline for interpreting susceptibility test results (17) and defined multidrug resistance as resistance to ≥3 antimicrobial drug families.

Statistical Analysis
We compared patient demographics, underlying diseases and conditions, and clinical and laboratory parameters between the C. striatum group and the MRSA group. We used χ² or Fisher exact test to compare categorical variables and Student t-test or Mann-Whitney U test to compare continuous variables. We analyzed changes in the proportions of pneumonic pathogens over time by using a χ² test for trend. We performed all analyses in SPSS Statistics 24.0 (IBM Corp., https://www.ibm.com) and considered p<0.05 statistically significant.

Results
Demographics, Underlying Diseases and Conditions, and Pneumonia Categories
During the study period, we identified a total of 1,740 patients with severe pneumonia. Among them, 27 had severe C. striatum pneumonia and 103 had severe MRSA pneumonia (Table 1). The median patient age in the C. striatum group was 72.0 years and in the MRSA group was 71.0 years. Solid cancer, diabetes mellitus, and structural lung diseases were the most common underlying conditions in both groups. More patients in the C. striatum group were immunocompromised (51.9% vs. 26.2%; p = 0.01); Most (70.4%) patients in the C. striatum group had HAP, 14.8% had healthcare-associated pneumonia (HCAP), 11.1% had ventilator-associated pneumonia, and 3.7% had CAP. HAP was significantly more common in the C. striatum group than the MRSA group (70.4% vs. 42.7%; p = 0.01); HCAP was more common in the MRSA group (32.0% vs. 14.8%; p = 0.08), albeit without statistical significance.

| Characteristic                              | Total, n = 130 | C. striatum, n = 27 | MRSA, n = 103 | p value |
|---------------------------------------------|----------------|----------------------|--------------|---------|
| Sex                                         |                |                      |              |         |
| M                                           | 92 (70.8)      | 18 (66.7)            | 74 (71.8)    | 0.60    |
| F                                           | 38 (29.2)      | 9 (33.3)             | 33 (32.0)    |         |
| Median age (interquartile range)            | 71.0 (63.8–77.0) | 72.0 (66.0–80.0)   | 71.0 (63.0–76.0) | 0.17    |
| Underlying disease or condition†            |                |                      |              |         |
| Solid cancer                                | 32 (24.6)      | 4 (14.8)             | 28 (27.2)    | 0.18    |
| Diabetes mellitus                           | 30 (23.1)      | 6 (22.2)             | 24 (23.3)    | 0.91    |
| Structural lung disease                     | 24 (18.5)      | 4 (14.8)             | 20 (19.4)    | 0.78    |
| Chronic obstructive lung disease            | 12 (9.2)       | 3 (11.1)             | 9 (8.7)      | 0.71    |
| Intestinal lung disease                     | 5 (3.8)        | 0                    | 5 (4.9)      | 0.58    |
| Bronchiectasis                              | 4 (3.1)        | 0                    | 4 (3.9)      | 0.58    |
| Destroyed lung due to tuberculosis          | 1 (0.8)        | 0                    | 1 (1.0)      | 1.00    |
| Pneumococia                                 | 1 (0.8)        | 0                    | 1 (1.0)      | 1.00    |
| Bronchiolitis obliterans                    | 1 (0.8)        | 1 (3.7)              | 0            | 0.21    |
| Hematologic malignancy                      | 13 (10.0)      | 5 (18.5)             | 8 (7.8)      | 0.14    |
| Liver cirrhosis                             | 11 (8.5)       | 2 (7.4)              | 9 (8.7)      | 1.00    |
| End-stage renal disease                     | 7 (5.4)        | 2 (7.4)              | 5 (4.9)      | 0.64    |
| Chronic renal failure                       | 6 (4.6)        | 3 (11.1)             | 3 (2.9)      | 0.10    |
| Congestive heart failure                    | 3 (2.3)        | 1 (3.7)              | 2 (1.9)      | 0.51    |
| Alcoholism                                  | 2 (1.5)        | 0                    | 2 (1.9)      | 1.00    |
| Cerebrovascular attack                      | 12 (9.2)       | 5 (18.5)             | 7 (6.8)      | 0.13    |
| Solid organ transplantation                 | 2 (1.5)        | 0                    | 2 (1.9)      | 0.63    |
| Hematopoietic stem cell transplantation      | 3 (2.3)        | 2 (7.4)              | 1 (1.0)      | 0.11    |
| Immunocompromised state‡                    | 41 (31.5)      | 14 (51.9)            | 27 (26.2)    | 0.01    |
| Recent chemotherapy                         | 23 (17.7)      | 7 (25.9)             | 16 (15.5)    | 0.26    |
| Recent surgery, <1 mo                       | 19 (14.6)      | 2 (7.4)              | 17 (16.5)    | 0.36    |
| Active smoker                               | 10 (7.7)       | 1 (3.7)              | 9 (8.7)      | 0.69    |
| Neutropenia, <500 cells/mL                  | 8 (6.2)        | 4 (14.8)             | 4 (3.9)      | 0.06    |
| Category of pneumonia                       |                |                      |              |         |
| Community-acquired                          | 6 (4.6)        | 1 (3.7)              | 5 (4.9)      | 1.00    |
| Healthcare-associated                      | 37 (28.5)      | 4 (14.8)             | 33 (32.0)    | 0.08    |
| Hospital-acquired                           | 63 (48.5)      | 19 (70.4)            | 44 (42.7)    | 0.01    |
| Ventilator-associated                      | 24 (18.5)      | 3 (11.1)             | 21 (20.4)    | 0.40    |

*Values are no. (%) except as indicated. MRSA, methicillin-resistant Staphylococcus aureus.
†Patients could have ≥1 underlying disease or condition.
‡Defined as ≥1 of the following conditions: daily receipt of immunosuppressants, including corticosteroids; HIV infection; solid organ or hematopoietic stem cell transplant recipient; receipt of chemotherapy for underlying malignancy during the previous 6 months; or underlying immune deficiency disorder.

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 28, No. 11, November 2022
Bacterial Pathogens Identified in Severe HAP Patients

We identified bacterial pathogens in 565 patients who had severe HAP during 2014–2019 (Table 2). The proportion of severe MRSA HAP decreased significantly, from 12.0% (24/200) in 2014–2015 to 2.7% (5/185) in 2018–2019 (p<0.01), whereas the proportion of severe C. striatum HAP increased significantly, from 1.0% (2/200) in 2014–2015 to 5.4% (10/185) in 2018–2019 (p<0.001). Among 75 HAP cases from which bacterial pathogens were identified in 2018–2019, C. striatum was responsible for 13.3% (10/75) of cases, which was the fourth most common pathogen, after Acinetobacter baumannii (30.7%), Klebsiella pneumoniae (21.3%), and Pseudomonas aeruginosa (14.7%).

Co-infections

We identified co-infection pathogens in 13 (48.1%) patients in the C. striatum group and 37 (35.9%) patients in the MRSA group (p = 0.25) (Table 3). Co-infection with other bacteria was more common in the MRSA group (25.2% vs. 7.4%; p = 0.045), whereas viral co-infection was more common in the C. striatum group (33.3% vs. 14.6%; p = 0.047). Fungal co-infection, which included 4 Aspergillus species and 1 Pneumocystis jirovecii, was only found in the C. striatum group (14.8% vs. 0%; p<0.01).

Clinical Manifestations and Laboratory Findings

Dyspnea, fever, sputum, and cough were the most common signs and symptoms in both groups (Table 4). Fever tended to be less common in the C. striatum group (66.7% vs. 82.5%; p = 0.07). The proportion of patients with septic shock at the time of ICU admission was significantly higher in the MRSA group (67.0% vs. 44.4%; p = 0.03). However, the proportion of mechanical ventilation, acute physiologic and chronic health evaluation (APACHE II) score, and sequential organ failure assessment (SOFA) score at the time of ICU admission were similar between the 2 groups. Peripheral leukocyte counts, platelet counts, and serum C-reactive protein levels also were similar between the 2 groups, but serum procalcitonin level was significantly higher in the MRSA group than the C. striatum group (median 0.3 ng/mL vs. 1.8 ng/mL; p<0.01).

C. striatum Gram Stain, Culture, and Antimicrobial Susceptibility Testing

On microscopic examination of Gram stain specimens, gram-positive rods were identified in 69.2% (18/26) of specimens. Among 27 cases, 10 were quantitative cultures and 17 were semiquantitative cultures. Bacterial counts were >10^6 CFU/mL in 8/10 quantitative cultures. Of the 17 semiquantitative culture specimens, 12 specimens were grade many (4+), 1 was grade many (3+), and 4 were grade few (1+). On microscopic examination of Gram stain specimens, gram-negative bacilli were identified in 18/26 (69.2%) of specimens. The most common pathogen was C. striatum (41.9%), followed by Streptococcus pneumoniae (30.8%) and Klebsiella pneumoniae (11.5%).

### Table 2. Bacterial pathogens detected among 565 adult patients with severe hospital-acquired pneumonia, Seoul, South Korea, 2014–2019

| Pathogens identified         | No. (%) patients | 2014–2015, n = 200 | 2016–2017, n = 180 | 2018–2019, n = 185 | Total, n = 565 | p value* |
|------------------------------|------------------|--------------------|--------------------|--------------------|----------------|----------|
| Staphylococcus aureus        |                  | 27 (13.5)          | 15 (8.3)           | 8 (4.3)            | 50 (8.8)       | <0.01    |
| Methicillin-susceptible      |                  | 3 (1.5)            | 0                  | 0                  | 6 (1.1)        | 0.24     |
| Methicillin-resistant        |                  | 24 (12.0)          | 15 (8.3)           | 5 (2.7)            | 44 (7.8)       | <0.01    |
| Corynebacterium striatum     |                  | 2 (1.0)            | 7 (3.9)            | 10 (5.4)           | 19 (3.4)       | 0.05     |
| Streptococcus pneumoniae     |                  | 4 (2.0)            | 2 (1.1)            | 1 (0.5)            | 7 (1.2)        | 0.43     |
| Legionella pneumophila       |                  | 1 (0.5)            | 0                  | 0                  | 2 (0.4)        | 0.61     |
| Moraxella catarrhalis        |                  | 0                  | 0                  | 1 (0.5)            | 1 (0.2)        | 0.36     |
| Streptococcus pyogenes       |                  | 0                  | 1 (0.6)            | 0                  | 1 (0.2)        | 0.34     |
| Nocardia species             |                  | 0                  | 0                  | 1 (0.5)            | 1 (0.2)        | 0.36     |
| Enteric gram-negative bacilli|                  | 18 (9.0)           | 22 (12.2)          | 20 (10.8)          | 60 (10.8)      | 0.59     |
| Klebsiella pneumoniae        |                  | 13 (6.5)           | 14 (7.8)           | 16 (8.6)           | 43 (7.6)       | 0.73     |
| Escherichia coli             |                  | 4 (2.0)            | 4 (2.2)            | 3 (1.6)            | 11 (1.9)       | 0.92     |
| Enterobacter cloacae         |                  | 1 (0.5)            | 3 (1.7)            | 2 (1.1)            | 6 (1.1)        | 0.54     |
| Citrobacter freundii         |                  | 1 (0.5)            | 2 (1.1)            | 0                  | 3 (0.5)        | 0.34     |
| Klebsiella oxytoca           |                  | 0                  | 0                  | 2 (1.1)            | 2 (0.4)        | 0.13     |
| Hafnia alvei                 |                  | 0                  | 1 (0.5)            | 0                  | 1 (0.2)        | 0.36     |
| Nonenteric gram-negative bacilli|             | 47 (23.5)          | 22 (12.2)          | 37 (20.0)          | 106 (18.8)     | 0.02     |
| Acinetobacter baumannii      |                  | 24 (12.0)          | 13 (7.2)           | 23 (12.4)          | 60 (10.6)      | 0.20     |
| Pseudomonas aeruginosa       |                  | 19 (9.5)           | 6 (3.3)            | 11 (5.9)           | 36 (6.4)       | 0.047    |
| Stenotrophomonas maltophilia |                  | 4 (2.0)            | 2 (1.1)            | 7 (3.8)            | 13 (2.3)       | 0.22     |
| Burkholderia cepacia         |                  | 0                  | 0                  | 1 (0.5)            | 1 (0.2)        | 0.36     |
| Acinetobacter lwolfii        |                  | 0                  | 1 (0.6)            | 0                  | 1 (0.2)        | 0.34     |
| Chryseobacterium indologenes |                  | 0                  | 1 (0.6)            | 0                  | 1 (0.2)        | 0.34     |
| Chryseobacterium meningosepticum |              | 1 (0.5)            | 0                  | 0                  | 1 (0.2)        | 0.40     |
| Chlamydia pneumoniae         |                  | 1 (0.5)            | 0                  | 0                  | 1 (0.2)        | 0.40     |

* p value based on χ² test for trend.
grade moderate (3+), 1 grade few (2+), and 3 were grade rare (1+) (Appendix Table, https://wwwnc.cdc.gov/EID/article/28/11/22-0273-App1.pdf). All 27 C. striatum isolates underwent antimicrobial susceptibility testing. All isolates were resistant to penicillin, ceftriaxone, erythromycin, and ciprofloxacin, and susceptible to vancomycin, and all isolates were multidrug resistant.

**Outcomes**

The mortality rates between the C. striatum and MRSA group showed no statistically significant differences: 30-day mortality (40.7% vs. 29.1%; p = 0.25), 60-day (48.1% vs. 42.7%; p = 0.61), and 90-day (59.3% vs. 50.5%; p = 0.42) (Table 5). In-hospital mortality rates were higher (70.4%) in the C. striatum group than in the MRSA group (52.4%), albeit without statistical significance (p = 0.09). Mortality rates were similar for C. striatum and MRSA in subgroups regardless of the patient’s immune status. We noted no statistically significant differences in the median length of ICU stay between the C. striatum and MRSA group, both 14 days (p = 0.33), nor in the length of hospital stay after ICU admission, 30 days for the C. striatum versus 29 days for the MRSA group (p = 0.48).

**Discussion**

We investigated the proportion and characteristics of severe C. striatum pneumonia compared with severe MRSA pneumonia. Although the proportion of severe MRSA HAP greatly decreased during 2014–2019, the proportion of severe C. striatum pneumonia sharply increased and surpassed that of severe MRSA pneumonia. C. striatum pneumonia was more commonly associated with immunocompromise, viral co-infection, and fungal co-infection. Mortality rates between the C. striatum and MRSA groups were comparable.

We found that the proportion of severe MRSA pneumonia decreased while severe C. striatum pneumonia greatly increased and that C. striatum emerged as one of the most common pathogens in patients with severe HAP. Strengthened infection control measures
during the study period might have contributed to the decline of severe MRSA pneumonia (18); however, severe *Corynebacterium striatum* pneumonia demonstrated the opposite trend. Several possible explanations for this discrepancy exist. First, detection of *C. striatum* from respiratory specimens in clinical laboratories increased, possibly because experience among laboratory staff accumulated over time. Also, new reliable identification techniques, such as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, were introduced and enabled precise and rapid detection and identification of bacteria in clinical samples, which might have contributed to the increased reports of severe *C. striatum* pneumonia (19,20). Second, *C. striatum* can be resistant to infection control measures and can adhere to abiotic surfaces and form biofilms on various medical devices, such as feeding tubes, endotracheal tubes, and ventilators (21,22). Some reports documented *C. striatum* strains with resistance to high-level disinfectants, such as 2% glutaraldehyde and other biocides (23,24). These findings suggest that appropriate environmental infection control measures for *C. striatum* should be further investigated and implemented. Finally, hospital outbreaks also might have contributed to the seeming discrepancy. Colonized patients and contaminated inanimate objects could be reservoirs for prolonged outbreaks. However, when we chronologically analyzed the occurrence patterns according to time and place, we could not find any suggestions of notable outbreaks. Clinical observation alone creates difficulties and limitations in distinguishing outbreaks; therefore, future studies should include more detailed

---

**Table 4. Clinical and laboratory characteristics of patients with severe *Corynebacterium striatum* pneumonia and methicillin-resistant *Staphylococcus aureus* pneumonia, Seoul, South Korea, 2014–2019**

| Characteristics                          | Total, n = 130 | *C. striatum*, n = 27 | MRSA, n = 103 | p value |
|------------------------------------------|----------------|-----------------------|---------------|---------|
| **Clinical manifestation**               |                |                       |               |         |
| Dyspnea                                  | 106 (81.5)     | 25 (92.6)             | 81 (78.6)     | 0.16    |
| Fever, temperature >38°C                 | 103 (79.2)     | 18 (66.7)             | 85 (82.5)     | 0.07    |
| Sputum                                   | 92 (70.8)      | 16 (59.3)             | 76 (73.8)     | 0.14    |
| Cough                                    | 57 (43.8)      | 11 (40.7)             | 46 (44.7)     | 0.72    |
| Altered mental status                    | 46 (35.4)      | 10 (37.0)             | 36 (35.0)     | 0.84    |
| Diarrhea                                 | 4 (3.1)        | 2 (7.4)               | 2 (1.9)       | 0.19    |
| Septic shock at ICU admission            | 81 (62.3)      | 12 (44.4)             | 69 (67.0)     | 0.03    |
| Mechanical ventilation                   | 127 (97.7)     | 27 (100)              | 100 (97.1)    | 1.00    |
| **Laboratory findings, median (IQR)**   |                |                       |               |         |
| Leukocyte count, cells/mL                | 10,950 (7,800–15,625) | 11,600 (4,800–15,900) | 10,700 (8,400–15,600) | 0.26 |
| Platelets, μL                            | 159 (81–242)   | 123 (55–230)          | 171 (102–245) | 0.14 |
| C-reactive protein, mg/dL                | 11.3 (5.5–19.3) | 13.6 (8.0–19.8)       | 10.8 (5.4–18.6) | 0.61 |
| Procalcitonin, ng/mL                     | 1.1 (0.3–3.9)  | 0.3 (0.1–1.3)         | 1.8 (0.4–4.2) | <0.01 |

*Values are no. (%) except as indicated. APACHE, acute physiology and chronic health evaluation; BAL, bronchoalveolar lavage; ICU, intensive care unit; IQR, interquartile range; MRSA, methicillin-resistant *Staphylococcus aureus*; SOFA, sequential organ failure assessment.

**Table 5. Outcomes of adult patients with severe *Corynebacterium striatum* and methicillin-resistant *Staphylococcus aureus* pneumonia, Seoul, South Korea, 2014–2019**

| Outcome                          | Total, n = 130 | *C. striatum*, n = 27 | MRSA, n = 103 | p value |
|----------------------------------|----------------|-----------------------|---------------|---------|
| **Death**                        |                |                       |               |         |
| Total                            | n = 103        | n = 27                | n = 103       | NA      |
| 30 days                          | 41 (31.5)      | 11 (40.7)             | 30 (29.1)     | 0.25    |
| 60 days                          | 57 (43.8)      | 14 (48.1)             | 44 (42.7)     | 0.61    |
| 90 days                          | 68 (52.3)      | 16 (53.8)             | 52 (50.5)     | 0.42    |
| In-hospital                      | 73 (56.2)      | 19 (70.4)             | 54 (52.4)     | 0.09    |
| **Death among patient categories**|                |                       |               |         |
| Nonimmunocompromised patients    | n = 89         | n = 13                | n = 76        | NA      |
| 30 days                          | 21 (23.6)      | 5 (38.5)              | 16 (21.1)     | 0.18    |
| 60 days                          | 31 (34.8)      | 5 (38.5)              | 26 (34.2)     | 0.76    |
| 90 days                          | 40 (44.9)      | 7 (53.8)              | 33 (43.4)     | 0.49    |
| In-hospital                      | 40 (44.9)      | 7 (53.8)              | 33 (44.4)     | 0.49    |
| Immunocompromised patients       | n = 41         | n = 14                | n = 27        | NA      |
| 30 days                          | 20 (48.8)      | 6 (42.9)              | 14 (51.9)     | 0.59    |
| 60 days                          | 26 (63.4)      | 8 (57.1)              | 18 (66.7)     | 0.55    |
| 90 days                          | 28 (68.3)      | 9 (64.3)              | 19 (70.4)     | 0.73    |
| In-hospital                      | 33 (80.5)      | 12 (85.7)             | 21 (77.8)     | 0.69    |
| **Median ICU stay, d (IQR)**     | 14.0 (8.0–26.3) | 12.0 (9.0–27.0)       | 14.0 (8.0–26.0) | 0.33 |
| **Median hospital stay after ICU admission, d (IQR)** | 29.5 (14.0–57.0) | 30.0 (16.0–81.0) | 29.0 (14.0–56.0) | 0.48 |

*Values are no. (%) except as indicated. ICU, intensive care unit; MRSA, methicillin-resistant *Staphylococcus aureus*; NA, not applicable.
typing analysis of *C. striatum* isolates to identify and curb possible healthcare-associated outbreaks.

In this study, viral or fungal co-infection was more common in the *C. striatum* group, whereas other bacterial co-infection was more common in the MRSA group. This finding could represent the host factor because a greater proportion of *C. striatum* patients were in an immunocompromised state, which would make them vulnerable to opportunistic infections. Of note, fewer cases of bacterial coinfection were diagnosed in the *C. striatum* group, but the cause for this difference is uncertain. One possible explanation is that *C. striatum* might influence the behavior and fitness of other bacteria. A recent study reported that *Corynebacterium* species can reduce the toxicity of *Staphylococcus aureus* by exhibiting decreased hemolysin activity and displaying diminished fitness of in vivo coinfection (26,27). Further targeted studies on this issue are needed.

We found that serum procalcitonin level was higher in the MRSA group than in the *C. striatum* group (median 1.8 ng/mL vs. 0.3 ng/mL). Some studies suggest that serum procalcitonin can be used as a marker for bacterial infection and to differentiate bacterial from viral infection or noninfectious causes of inflammation (26,27). In 2017, a group of researchers in China reported that the median serum procalcitonin level of an *S. aureus* bacteremia group of patients was higher (1.18 ng/mL than that of a coagulase-negative staphylococci bacteremia group (0.21–0.31 ng/mL) (28). We speculate that infections caused by low-virulence bacteria, such as *C. striatum* in our study, might have low levels of procalcitonin and this warrants further investigation.

Mortality rates were similarly high in both groups, but septic shock at the time of initial clinical manifestation was less common in the *C. striatum* group. Immunocompromised conditions were more common in the *C. striatum* group, which could suggest that *C. striatum* is less virulent than MRSA. Host factor might contribute to the development of severe *C. striatum*-associated pneumonia and the subsequent outcomes; however, we noted no statistically significant differences in mortality rates between the 2 groups after stratification by immunocompromised conditions. The existence of co-infection and pathogen types (e.g., other bacteria, viruses, fungi) involved might have affected mortality rates, but we were unable to effectively evaluate each effect because of the small number of patients in each subgroup.

The first limitation of our study is that we used a single-center design and our results might not be replicable in other centers or hospital systems. In addition, as we mentioned previously, we were not able to effectively evaluate the sole contribution of *C. striatum* because co-infection with other pathogens was common among the patient cohort. Finally, we included all *C. striatum* isolates from sputum, endotracheal aspirate, and bronchoalveolar lavage, but the cultures were mostly semiquantitative, and some of the *C. striatum* isolates might have been nonpathogenic colonizers. A 2020 study from the United States reported that normal respiratory flora appears to have caused one quarter of CAP cases (29), which supports our finding that bacteria previously considered as colonizers or normal flora can be a cause of pneumonia.

In conclusion, we found *C. striatum* was associated with severe HAP. Patients with severe *C. striatum* pneumonia showed similar clinical and laboratory features as patients with severe MRSA pneumonia, and both infections were associated with high mortality rates. Further investigations could clarify incidence, clinical characteristics, and outcomes of severe *C. striatum* pneumonia in critically ill adults and determine whether infections are due to colonization, or community- or healthcare-acquired infections. Clinicians should be aware of this emerging pathogen as a possible cause for severe pneumonia, especially among immunocompromised patients.

This work was supported by the Asan Institute of Life Sciences (grant no. 2010-0079) and generous gifts from Sam Won Song.

About the Author

Dr. Lee is a physician at Asan Medical Center, University of Ulsan College of Medicine in Seoul, South Korea. Her research interests include infectious diseases and clinical microbiology. Dr. Huh is an intensivist and professor at Asan Medical Center, University of Ulsan College of Medicine in Seoul, South Korea. Her main research interest is the pathogenesis and management of acute respiratory distress syndrome.

References

1. Funke G, von Graevenitz A, Claridge JE III, Bernard KA. Clinical microbiology of coryneform bacteria. Clin Microbiol Rev. 1997;10:125–59. https://doi.org/10.1128/CMR.10.1.125
2. Chen FL, Hsieh PR, Teng SO, Ou TY, Lee WS. *Corynebacterium striatum* bacteremia associated with central venous catheter infection. J Microbiol Immunol Infect. 2012;45:255–8. https://doi.org/10.1016/j.jmii.2011.09.016
3. Hong HL, Koh HI, Lee AJ. Native valve endocarditis due to *Corynebacterium striatum* confirmed by 16S ribosomal RNA sequencing: a case report and literature review. Infect Chemother. 2016;48:239–45. https://doi.org/10.3947/ic.2016.48.3.239
4. Bowssteed TT, Santiago SM Jr. Pleuropulmonary infection due to *Corynebacterium striatum*. Br J Dis Chest. 1990;74:198–200. https://doi.org/10.1016/0007-4971(80)90035-2
